The MiniMed™ 670G Hybrid Closed-Loop (HCL) System improves glucose control and reduces glucose variability. There are no data whether HCL Systems achieve different results in T1DM patients treated with multiple daily injection and continuous glucose monitoring (MDI+CGM) or integrated insulin pump and CGM (CSII+CGM) or sensor-augmented pump therapy with predictive low glucose suspend (PLSG) feature. Aim of our study was to evaluate the effect on metabolic control of the switch from MDI+CGM, CSII+CGM or SAP with PLGS in type 1 diabetic patients.
Baseline clinical characteristics were presented as means and SD. One-way repeated measures ANOVA test was used to verify changes at 12 weeks from baseline in mean blood glucose, SD, TIR, TAR, TBR, Total Insulin dose and % of Basal Insulin.
32 adults with type 1 diabetes (mean age 41,9 + 9,7; duration of diabetes 22 + 12,5; BMI 24,7 + 4,1), who had been using MDI + CGM (n=12) or CSII + CGM (n=11) or SAP therapy (n=9) were evaluated after switching to the 670G System. After 12 weeks a reduction of HbA1c (-0,39% p <0.001), mean glucose and SD (-9,7 mg/dl and 5,8 mg/dl p 0,003 and < 0,001) were observed. TIR increased significantly (+9,7% p < 0,001), in parallel with a reduction in TAR (-8,6% p 0,003) and TBR (-0,87% p 0,044).
Switching to the 670G System significantly improved glucose control in patients previously treated with MDI+CGM and CSII+CGM. Furthermore, similar results were obtained in patients treated with SAP with PLGS feature.